Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) CEO Sells $383,400.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani sold 5,400 shares of the firm’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $71.00, for a total value of $383,400.00. Following the sale, the chief executive officer directly owned 339,089 shares of the company’s stock, valued at $24,075,319. This represents a 1.57% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nikhil Lalwani also recently made the following trade(s):

• On Tuesday, August 25th, Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $74.30, for a total transaction of $401,220.00.

ANI Pharmaceuticals Stock Performance

Shares of ANIP traded up $1.48 during trading hours on Wednesday, hitting $73.59. The company had a trading volume of 431,593 shares, compared to its average volume of 377,903. The firm has a market cap of $1.69 billion, a price-to-earnings ratio of 15.86 and a beta of 0.45. The business has a fifty day moving average of $76.69 and a 200-day moving average of $78.14. ANI Pharmaceuticals, Inc. has a 12 month low of $69.58 and a 12 month high of $98.55. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. The business had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. ANI Pharmaceuticals’s quarterly revenue was up 25.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current fiscal year.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in ANIP. The Manufacturers Life Insurance Company raised its position in ANI Pharmaceuticals by 1.5% in the first quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock valued at $736,000 after purchasing an additional 143 shares during the last quarter. Oregon Public Employees Retirement Fund raised its stake in shares of ANI Pharmaceuticals by 5.1% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 4,086 shares of the specialty pharmaceutical company’s stock valued at $323,000 after acquiring an additional 200 shares during the last quarter. Hantz Financial Services Inc. raised its stake in shares of ANI Pharmaceuticals by 70.3% during the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after acquiring an additional 249 shares during the last quarter. ProShare Advisors LLC lifted its holdings in shares of ANI Pharmaceuticals by 8.0% during the fourth quarter. ProShare Advisors LLC now owns 4,520 shares of the specialty pharmaceutical company’s stock worth $357,000 after purchasing an additional 336 shares during the period. Finally, New York State Teachers Retirement System lifted its holdings in shares of ANI Pharmaceuticals by 1.6% during the first quarter. New York State Teachers Retirement System now owns 23,268 shares of the specialty pharmaceutical company’s stock worth $1,789,000 after purchasing an additional 356 shares during the period. Institutional investors own 76.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Leerink Partners began coverage on ANI Pharmaceuticals in a report on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 price objective on the stock. Canaccord Genuity Group dropped their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a report on Monday, August 10th. Wall Street Zen cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings downgraded shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Finally, Guggenheim lowered their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, ANI Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $105.57.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI’s portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.